DMD and muscular dystrophy: Besides testing novel pharmacological strategies [257,381,382,383,384] and immunomodulatory interventions [355,356,357,358,364], a variety of innovative therapeutic approaches are currently evaluated in the field of muscular dystrophy [385,386,387,388,389], including exon skipping [148,390,391,392,393], genomic editing [394,395,396], codon read-through [397], gene replacement with the help of adeno-associated viral vectors [398,399,400,401,402], dystrophin substitution with its autosomal homolog utrophin [403,404,405], and muscle stem cell therapy [406,407,408,409].